Table 5 Changes in molecular markers revealed by the randomised controlled trial (Study 2)

From: Effects of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic treatment: analysis of molecular alterations by a randomised controlled trial

 

Eradicated group

Non-eradicated group

 
 

Improved (%)

Unchanged (%)

Worsened (%)

Improved (%)

Unchanged (%)

Worsened (%)

 
 

+→−

+→+

−→−

−→+

+→−

+→+

−→−

−→+

P -value*

MSI

14 (73.7)

5 (26.3)

—

10 (58.8)

7 (41.2)

—

0.48

hMLH1

4 (21.1)a

11 (57.9)

4 (21.1)

2 (11.8)a

12 (70.6)

3 (17.6)

0.66a

CDKN2A

1 (5.3)b

18 (94.7)

0 (0)

0 (0)b

17 (100)

0 (0)

>0.99b

APC

0 (0)c

18 (94.7)

1 (5.3)

2 (11.8)c

14 (82.4)

1 (5.9)

0.22c

mAb Das-1 reactivity

1 (5.3)d

15 (78.9)

3 (15.8)

1 (5.9)d

11 (64.7)

5 (29.4)

>0.99d

  1. Abbreviations: MSI=microsatellite instability; APC=adenomatous polyposis coli; mAb=monoclonal antibody.P-value*, Fisher’s exact test.
  2. a,b,c,dP-values indicate the comparison in the prevalence of improved cases between the eradicated and non-eradicated groups.
Back to article page